anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a sulphuric acid esterified raw lacquer polysaccharide with bioactivity. The degree of the sulphuric acid esterification of the polysaccharide is between 0.1 and 1.7, and the molecular weight is between 7.3*10<4> and 1.1*10<4>. A preparation method of the sulphuric acid esterified raw lacquer polysaccharide comprises the following steps: a raw lacquer polysaccharide is dissolved or suspended in a drying solvent according to the weight ratio of 1:50 to 100, and the mixture is stirred at 40 to 100 DEG C for 10 to 30 minutes; subsequently, a pyridine sulfur trioxide compound with the molar weight of 1 to 4 times higher than that of raw lacquer polysaccharide residues or a chlorosulfonic acid pyridine mixture according to the volume ratio of 1:2 to 4:1 is added for reacting for 0.5 to 4 hours; the reaction mixture is cooled by ice bath; ice water with the volume of 1/3 to 1/2 times higher than that of the solvent is added; the mixture is neutralized by 5 to 20 wt% of NaOH; then, the mixture is dialyzed in distilled water; the dialysate is decompressed, distilled and concentrated at 30 to 70 DEG C, and then is precipitated by anhydrous alcohol; precipitates are dried in a vacuum mode by P2O5 to obtain the required sulphuric acid esterified raw lacquer polysaccharide. The present invention has the advantage of good repetitiveness. The obtained sulphuric acid esterified polysaccharide not only has high molecular weight, but also has high substitution value, anticoagulant activity and antiviral activity. The sulphuric acid esterified polysaccharide can replace heparin for preparing anticoagulant drugs.
<P>PROBLEM TO BE SOLVED: To readily correct mismatching information in a medical image management system.  <P>SOLUTION: A server 20 detects item information which is not matched with basic information DB 27, reads attached information stored in a mismatching folder 252 and displays it on a display part 23 in a form of a list. Patient information and inspection information, which correspond to inputted patient ID and inspection ID, are acquired from RIS as RIS information and they are displayed on the display part 23 as correction candidate information. Basic information, corresponding to patient ID and inspection ID, are similarly acquired from the basic information DB 27, and they are displayed as correction candidate information. Updated information, where mismatched item information is corrected, is created based on information selected by a manager among attached information, RIS information and basic information. Attached information or basic information DB 27 is updated, based on the created updating information.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
INTRODUCTION: Cardiovascular surgery risk prediction models are widely applied in medical practice. However, they have been criticized for their low methodological quality and scarce external validation. An additional limitation added in Latin America is that most of these models have been developed in the United States or Europe, which present marked geographical differences. The objective of this study is to characterize the postoperative clinical events of cardiovascular surgeries with the use of cardiopulmonary bypass pump in a local setting and to evaluate the prediction of postoperative mortality using the EuroSCORE II predictive model.
METHODS: Cross-sectional study in an urban university hospital in Buenos Aires. Patients ≥21 years of age were included, with a clinical indication for on-pump cardiovascular surgery. Patients with incomplete clinical data regarding EuroSCORE II variables or in-hospital survival, ≥95 years of age, or undergoing heart transplantation were excluded.
RESULTS: 195 patients were enrolled. Postoperative mortality estimated by EuroSCORE II presented a clear underestimation of risk (3.0% vs 7.7%). Discrimination (AUC = 0.82; 95% CI 0.74-0.92) and goodness of fit of the model were adequate (χ2 = 7.91; p = 0.4418). The most frequent postoperative complications were postoperative heart failure (35.9%), vasoplegic shock (13.3%), and cardiogenic shock (10.26%).
CONCLUSION: The EuroSCORE II is an appropriate tool to discriminate between different risk categories in patients undergoing on-pump cardiovascular surgery, although it underestimates the risk.
The primary objective of the study is to test a personalized approach for prescribing weight loss strategies in overweight adults participating in a weight loss intervention and to determine if a personalized approach can optimize weight loss compared to a standard behavioral weight loss intervention. Thus, all participants will receive a behavioral weight loss intervention delivered via remote counseling and digital tools including a smart phone app, Wi-Fi- enabled smart scale, physical activity tracker. Participants in the personalized group will also use a continuous blood glucose monitoring (CGM) device.

The differences between the two groups will be the approach used to recommend diet and physical activity changes. The study will compare a Standard Behavioral Weight Loss (BWL) approach tested in numerous previous studies and consistent with current clinical practice, to a Personalized Behavioral Weight Loss (PBWL) approach that tests a combination of diet and physical activity prescriptions to determine the best "fit" for the participant. The PWBL group will actively use CGM information during the intervention period to inform diet and activity behaviors. Participants will be randomized in a 3:1 ratio to PBWL or BWL (i.e., 30 to PBWL and 10 to BWL).

1. Behavioral Weight Loss: The BWL group will receive a standard weight loss intervention based on the evidence-based interventions currently being recommended for clinical practice, with general recommendations for caloric reductions based on starting weight and aimed at achieving a 1-2 lb. average weekly weight loss, and progressive weekly increases of physical activity. Supporting behavioral lessons adapted from materials used in the Diabetes Prevention Program, a landmark behavioral weight loss intervention, will also be delivered. The weight loss 'prescription' will remain consistent throughout the 3 month trial.
2. Personalized Behavioral Weight Loss: The PBWL group will receive a weight loss intervention that is personalized for diet and physical activity recommendations based on a testing period where various approaches to eating and physical activity that may result in differential adherence and response are tested. Calorie recommendations will be based on measured resting energy expenditure and expected activity levels and aimed at achieving a 1-2 lb. average weekly weight loss. In the initial weeks, participants will test various diet and physical activity prescriptions. Following this period, the optimal combination will be identified by the participant, in consultation with their interventionist, based on measured blood glucose, weight loss, hunger and ability to adhere to the prescription. Diet composition (percentage of calories from fat, carbohydrates, and protein) will be personalized along with meal frequency and physical activity goals. This group will receive the same supporting behavioral lessons as the BWL group along with additional resources specific to their personalized prescription. The weight loss 'prescription' will vary across the 3-month trial based on response to treatment.
No clinically significant alterations in penciclovir pharmacokinetics were observed following single-dose administration of 500 mg famciclovir after pretreatment with multiple doses of allopurinol, cimetidine, theophylline, zidovudine, promethazine, when given shortly after an antacid (magnesium and aluminum hydroxide), or concomitantly with emtricitabine. No clinically significant effect on penciclovir pharmacokinetics was observed following multiple-dose (three times daily) administration of famciclovir (500 mg) with multiple doses of digoxin.

Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.

The conversion of 6-deoxy penciclovir to penciclovir is catalyzed by aldehyde oxidase. Interactions with other drugs metabolized by this enzyme and/or inhibiting this enzyme could potentially occur. Clinical interaction studies of famciclovir with cimetidine and promethazine, in vitro inhibitors of aldehyde oxidase, did not show relevant effects on the formation of penciclovir. Raloxifene, a potent aldehyde oxidase inhibitor in vitro, could decrease the formation of penciclovir. However, a clinical drug-drug interaction study to determine the magnitude of interaction between penciclovir and raloxifene has not been conducted.
BACKGROUND: Substance use disorders (SUDs) have been consistently shown to exhibit moderate intergenerational continuity (1-3). While much research has examined genetic and social influences on addiction, less attention has been paid to clients' and lay persons' perceptions of genetic influences on the heritability of SUD (4) and implications for treatment.
METHODS: For this qualitative study, twenty-six structured Working Model of the Child Interviews (WMCI) were conducted with mothers receiving inpatient SUD treatment. These interviews were thematically analyzed for themes related to maternal perceptions around intergenerational transmission of substance use behaviours.
RESULTS: Findings show that over half of the mothers in this sample were preoccupied with their children's risk factors for addictions. Among this group, 29% spontaneously expressed concerns about their children's genetic risk for addiction, 54% shared worries about their children's propensity for addiction without mentioning the word gene or genetic. Additionally, 37% had challenges in even discussing their children's future when prompted. These concerns mapped onto internal working models of attachment in unexpected ways, with parents who were coded with balanced working models being more likely to discuss intergenerational risk factors and parents with disengaged working models displaying difficulties in discussing their child's future.
CONCLUSION: This research suggests that the dominant discourse around the brain-disease model of addictions, in its effort to reduce stigma and self-blame, may have unintended downstream consequences for parents' mental models about their children's risks for future addiction. Parents receiving SUD treatment, and the staff who deliver it, may benefit from psychoeducation about the intergenerational transmission of SUD as part of treatment.
Participants will undergo a first day of testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will then consume a Western diet for 7 days before a second day of identical testing (blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies).
Compositions for cosmetic, pharmaceutical, food or veterinary use, intended to delay ageing in mammals through their activating action on genes of Sirtuin type, which genes are naturally activated during calorie restriction. These compositions are characterized in that they contain one or more oligomers of resveratrol, and more particularly ε-viniferin, and/or glucosides and/or the corresponding esters of these oligomers and/or the natural extracts containing them. It has been shown, on several living species, that calorie restriction extends the lifespan and reduces the deleterious effects of ageing. Studies on primates and on human populations have corroborated these results. It has also been shown that calorie restriction activates certain genes called Sirtuins (silent information regulator). Consequently, natural or synthetic ingredients or molecules which activate genes and make it possible to do without a difficult long-term calorie restriction have been sought. Resveratrol or 3,4',5-trihydroxystilbene is known to activate certain genes of the Sirtuin family. The present invention describes, for the first time, the activation of these genes by oligomers of resveratrol, in particular Pε-viniferin. A specific test has been carried out and shows that Pε-viniferin and an extract of vine shoot containing it, and also other oligomers of resveratrol, completely activate the SIRTl enzyme. Cosmetic, pharmaceutical, food and veterinary compositions are described by way of examples. The cosmetic composition described, and which contains an extract of vine shoot, was subjected to tests which showed that it is completely innocuous on human skin. It was also subjected to a test on humans showing its effectiveness in decreasing the effects of ageing. The invention claims cosmetic, pharmaceutical, food and veterinary compositions whose activating action on Sirtuin genes makes it possible to delay ageing in mammals and combat the harmful effects thereof.
The safety and effectiveness of nelarabine for relapsed or refractory T-ALL and T-LBL has been established in pediatric patients age 1 year and older. The effectiveness of nelarabine in pediatric patients is supported by one single-arm clinical trial, and safety has been assessed in 165 pediatric patients age 1 year and older across multiple Phase I and Phase II trials. The trial establishing efficacy included 84 patients age 21 years and younger, who had relapsed or refractory T-ALL or T-LBL. The most frequent adverse reactions of any grade occurring on treatment in this study were hematologic laboratory abnormalities. Hematologic toxicity observed in the pediatric population was higher than that seen in the adult population [see Dosage and Administration (2.1), Adverse Reactions (6.1), Clinical Studies (14.2)]. 

Nervous system adverse reactions have been reported for 42% of pediatric patients across the Phase I and Phase II trials. The incidence of nervous system adverse reactions was less in the pediatric population than that seen in adult patients with relapsed/refractory T-ALL/T-LBL [see Adverse Reactions (6.1)]. 

In a phase III study of nelarabine in combination with multi-agent chemotherapy as first-line therapy, there were 411 patients with T-ALL or T-LBL treated with nelarabine. The safety profile in the 357 patients age 1 to 16 years was consistent with that seen in older patients in the study [see Adverse Reactions (6.1)].

Due to lack of long-term follow up data, a determination of the impact of nelarabine on the growth and pubertal development of pediatric patients cannot be made.
NEW MATERIAL:A benzimidazole derivative expressed by formula I (R is alkylcarbonyl, alkoxy or halogen). EXAMPLE:5-Acetyl-2-[(2-dimethylaminobenzyl)sulfinyl]benzimidazol-e. USE:With antiulcer action, gastric mucosa protection action and gastric acid secretion inhibitory action and useful as a pharmaceutical, used for treating and preventing gastrointestinal inflammatory diseases, e.g. gastritis, gastric ulcer, duodenal ulcer, hemorrhage of upper digestive tracts, Zollinger-Ellision syndrome, etc., capable of being administered for a long period and having great safety. PREPARATION:As shown in the reaction formulas, a compound expressed by formula II is reacted with a compound expressed by formula III (X is halogen, e.g. Cl, Br, etc., or eliminative group, e.g. p-toluenesulfonyloxy, etc.) in the presence of an alkali in a solvent, e.g. methanol, etc., to give a compound expressed by formula IV, which is then oxidized to afford the aimed compound expressed by formula I.
Subjects aged from 6 - \<12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kg received a dose (equivalent to 20 mg in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
Bromocriptine mesylate is a dopamine receptor agonist, which activates post-synaptic dopamine receptors. The dopaminergic neurons in the tuberoinfundibular process modulate the secretion of prolactin from the anterior pituitary by secreting a prolactin inhibitory factor (thought to be dopamine); in the corpus striatum the dopaminergic neurons are involved in the control of motor function. Clinically, bromocriptine significantly reduces plasma levels of prolactin in patients with physiologically elevated prolactin as well as in patients with hyperprolactinemia. The inhibition of physiological lactation as well as galactorrhea in pathological hyperprolactinemic states is obtained at dose levels that do not affect secretion of other tropic hormones from the anterior pituitary. Experiments have demonstrated that bromocriptine induces long-lasting stereotyped behavior in rodents and turning behavior in rats having unilateral lesions in the substantia nigra. These actions, characteristic of those produced by dopamine, are inhibited by dopamine antagonists and suggest a direct action of bromocriptine on striatal dopamine receptors.

Bromocriptine mesylate is a nonhormonal, nonestrogenic agent that inhibits the secretion of prolactin in humans, with little or no effect on other pituitary hormones, except in patients with acromegaly, where it lowers elevated blood levels of growth hormone in the majority of patients.

Bromocriptine mesylate produces its therapeutic effect in the treatment of Parkinson’s disease, a clinical condition characterized by a progressive deficiency in dopamine synthesis in the substantia nigra, by directly stimulating the dopamine receptors in the corpus striatum. In contrast, levodopa exerts its therapeutic effect only after conversion to dopamine by the neurons of the substantia nigra, which are known to be numerically diminished in this patient population.
Patients receiving mifepristone may experience adrenal insufficiency. Because serum cortisol levels remain elevated and may even increase during treatment with mifepristone, serum cortisol levels do not provide an accurate assessment of hypoadrenalism in patients receiving mifepristone. Patients should be closely monitored for signs and symptoms of adrenal insufficiency, including weakness, nausea, increased fatigue, hypotension, and hypoglycemia. If adrenal insufficiency is suspected, discontinue treatment with mifepristone immediately and administer glucocorticoids without delay. High doses of supplemental glucocorticoids may be needed to overcome the glucocorticoid receptor blockade produced by mifepristone. Factors considered in deciding on the duration of glucocorticoid treatment should include the long half-life of mifepristone (85 hours).

Treatment with mifepristone at a lower dose can be resumed after resolution of adrenal insufficiency. Patients should also be evaluated for precipitating causes of hypoadrenalism (infection, trauma, etc.).
NEW MATERIAL:A compound of formula I (R<1> is H, halogen or acyl; R<2> and R<3> are H, lower alkyl, aryl or aralkyl; Y is alkylene; n is 2 or 3). EXAMPLE:3-(2-Thienylmethyl)-2-oxazolidinone. USE:An antiulcer agent capable of exhibiting improved activity in prevention and treatment of ulcers in the stomach and duodenum. PREPARATION:A novel thiophene aminoalcohol derivative of formula II is reacted with a carbonyl compound of formula III (X is Cl or 1-imidazolyl) in a solvent, e.g. benzene or toluene, at 0-80 deg.C to afford the compound of formula I . The compound of formula II is obtained by reacting a thiophenecarboxylic acid derivative of formula IV (Y' is alkylene or a simple bond) with an aminocarboxylic acid derivative of formula V, and reducing the resultant reaction product with a suitable reducing agent, e.g. aluminum hydride.
We present the case of a 79-year-old man with rapidly progressive myopathy as the initial manifestation of light chain amyloidosis associated with multiple myeloma. The patient experienced progressive lower limb weakness resulting in difficulty climbing stairs. Ancillary tests revealed slightly elevated serum creatine kinase levels. The electromyogram revealed a diffuse myogenic pattern while muscle MRI indicated fatty replacement of the quadriceps muscles. Muscle biopsy revealed the presence of amyloid deposits in the vessel walls. An elevated level of lambda (246 mg/L) light chain was detected. The bone marrow aspiration results were consistent with the diagnosis of multiple myeloma. In conclusion, even if amyloid myopathy is a rare condition, routine screening for amyloid deposits in muscle biopsy is crucial and should be performed systematically. In the present case, it enabled a rapid diagnosis and the beginning of treatment.
Chronic Obstructive Pulmonary Disease (COPD) is a set of diseases that cause airflow obstruction, breathing difficulties, wheezing and chest tightness. Risk factors are smoking and non-tobacco-smoking, the use of biomass fuel and open fires for domestic purposes in poorly ventilated households. Physiotherapy is an important component of multidisciplinary therapies. Airway clearing, pulmonary rehabilitation, inspiratory muscle training, and non-invasive ventilation is the prior treatment .The aim of this study will be to find the effects of diaphragm and abdominal muscle training on pulmonary function testing and dyspnea among COPD patients .

It will be a randomized control trial at Services Hospital Lahore through convenience sampling technique which will be allocated through simple random sampling through sealed opaque enveloped in to Group A and Group B . Group A: patients will be treated with basic breathing technique whereas Group B: will be treated by will be breathing technique along with diaphragm and abdominal training. The study will be completed within 6 months after synopsis approval from ethical Committee of RCRS \& AHS . Data will be entered and analyzed by SPSS version 25. After assessing the normality of data , it will be decided either parametric or non-parametric test will be use within a group or between two groups.
BACKGROUND: Recurrent miscarriage (RM) is defined as the occurrence of at least two or three subsequent miscarriages within the 20th -24th weeks of pregnancy. The primary objective of this study was to investigate whether histidine-rich glycoprotein C633T single nucleotide polymorphism (HRG C633T SNP) statistically correlates with the occurrence of RM among Iranian women.
METHODS AND RESULTS: Blood samples from 200 women were taken at the outset of the study. Then, the blood samples of 100 women who had a record of RM (case group) were compared with the other 100 women's blood samples who had no record of RM (control group). Following DNA extraction, the polymorphism of histidine-rich glycoprotein C633T (HRG C633T) for every case was specified and all women were genotyped by the amplification-refractory mutation system (ARMS) method. The results of the study revealed that there was a statistically significant difference between T/T genotype (OR = 3.5, CI (1.39-8.77), p = 0.007), and C/T genotype (OR = 1.83, CI (0.99-3.37), p = 0.05) in the case and control groups. Also, a statistically significant association was observed in T allelic frequency in the RM participants compared to the control group (OR = 2.01, CI (1.31-3.09), p = 0.01).
CONCLUSIONS: The present study determined that there was a statistically significant relationship between HRG C633T SNP and increased RM regarding allelic and genotypical aspects. Moreover, it became apparent that women with homozygous T/T genotype were more susceptible to the risk of RM.